Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet

Benzinga.com  January 9, 2018

Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views

Benzinga.com  January 9, 2018

Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial

GlobeNewswire January 9, 2018

Axsome Therapeutics to Present at Biotech Showcase 2018

GlobeNewswire December 19, 2017

Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation

GlobeNewswire December 14, 2017

Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering

GlobeNewswire December 6, 2017

Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market

GlobeNewswire December 1, 2017

Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine

GlobeNewswire November 28, 2017

Axsome Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 8, 2017

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 18, 2017

Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017

GlobeNewswire September 7, 2017

Axsome Therapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire August 9, 2017

Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial

GlobeNewswire July 25, 2017

Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation

GlobeNewswire July 17, 2017

Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer

GlobeNewswire July 6, 2017

Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors

GlobeNewswire June 19, 2017

Axsome Therapeutics Reports First Quarter 2017 Financial Results

GlobeNewswire May 9, 2017

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation

GlobeNewswire May 8, 2017

Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

GlobeNewswire March 29, 2017

Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference

GlobeNewswire March 23, 2017